Long intergenic non-protein coding RNA 1635 (LINC01635)

Long intergenic non-protein coding RNA 1635 (LINC01635) is a long non-coding RNA (lncRNA) highly expressed in normal testis and a variety of human cancers, particularly non-small cell lung carcinoma (NSCLC)[1][3][4][5][7]. It promotes the proliferation and metastasis of NSCLC cells both in vitro and in vivo. Mechanistically, LINC01635 functions as a miRNA sponge for miR-455-5p, regulating downstream tumor-associated genes involved in proliferation and metastasis[1][3][7]. Silencing LINC01635 results in suppressed NSCLC progression. Due to its unique expression pattern (cancer/testis antigen lncRNA) and role in oncogenic processes, LINC01635 is considered a potential therapeutic target and biomarker in cancer, particularly lung cancer[1][3][4][7]. LINC01635 is not a conventional receptor, enzyme, transporter, or transcription factor, but rather a member of the lncRNA class, which functions in epigenetic and post-transcriptional regulation[1][3][5]. No direct small-molecule drugs or biologics targeting LINC01635 are described in current literature[1][3]. The molecule's importance comes primarily from its regulatory effect on oncogenic pathways, particularly through miRNA interaction, making it a secondary mediator or target in lncRNA-directed therapeutic approaches[1][3]. If you require mapping to a drug or protein target database, note that lncRNAs such as LINC01635 often do not have standardized chemical modulators or clinical precedence as "drug targets," but they are emerging targets in nucleic acid-based therapies and cancer biomarker research[1][3].

Other names

LINC01635long non-coding RNA 1635

Acts as a competing endogenous RNA (ceRNA) or miRNA sponge for miR-455-5p, thereby regulating the expression of miR-455-5p-targeted tumor-related genes[1][3][7].